3-Methyl-PCP, also known as 3′-Methyl-PCP, meta-Methyl-PCP, or 3-Me-PCP, is a designer drug appreciated for its dissociative effects and commonly used for recreational purposes. This compound is a derivative of arylcyclohexylamine and shares chemical connections with substances like 3′-MeO-PCP and 3′-Me-PCPy. Despite its initial synthesis dating back to the 1960s, 3-Methyl-PCP remained off the radar until it surfaced on the illicit market in Hungary in September 2020. Subsequently, it was classified as illegal in Hungary in April 2021.

IUPAC name
CAS Number2201-30-1 
PubChem CID611899
Chemical and physical data
Molar mass257.421 g·mol−1


1. What is 3-Methyl-PCP?

  • 3-Methyl-PCP, also referred to as 3′-Methyl-PCP, meta-Methyl-PCP, or 3-Me-PCP, is a recreational designer drug known for its dissociative effects.

2. How is 3-Methyl-PCP used?

  • 3-Methyl-PCP is typically used recreationally. It can be ingested orally, inhaled, or insufflated (snorted). The method of consumption may vary among individuals.

3. What are the effects of 3-methyl-PCP?

  • The effects of 3-methyl-PCP are characterized by dissociation, altered perception of reality, and a sense of detachment from one’s surroundings.

4. Is 3-Methyl-PCP legal?

  • The legal status of 3-Methyl-PCP differs by country and region. It’s essential to be aware of the laws in your specific area regarding the possession and use of this substance.

5. Is 3-methyl-PCP safe to use?

  • The safety of using 3-Methyl-PCP is a subject of concern, as its long-term effects and potential risks are not well-documented. Like many designer drugs, there can be health risks associated with use, including unknown purity and possible adverse reactions.

6. What are the risks and side effects of using 3-methyl-PCP?

  • Common side effects may include nausea, disorientation, hallucinations, and impaired motor skills. Overdosing can lead to more severe symptoms such as anxiety, confusion, and potentially life-threatening conditions.

7. Can 3-methyl-PCP be addictive?

  • There is a potential for psychological dependence with repeated use, but it is not considered highly physically addictive like some other substances.

8. How can I reduce the risks associated with 3-methyl-PCP use?

  • If you choose to use 3-methyl-PCP, it’s essential to start with a low dose, be in a safe environment, and have someone you trust present. Avoid mixing it with other substances and be aware of its potential adverse effects.

9. Is there a safe or recommended dosage for 3-methyl-PCP?

  • The dosage can vary based on an individual’s tolerance and experience. Starting with a low dose and monitoring your body’s response is advisable.

10. Where can I find help or support for 3-Methyl-PCP-related issues?

  • If you or someone you know is struggling with substance use or addiction, it’s crucial to seek professional help. Reach out to addiction treatment centers or healthcare providers for guidance and support.

Please note that this information is for informational purposes only, and the use of designer drugs like 3-Methyl-PCP carries risks and legal implications. Always prioritize your health and safety and be aware of the laws in your area.


  1. In a study conducted in February 2010, Linders J, Furlano DC, Mattson MV, Jacobson AE, and Rice KC undertook the “Synthesis and preliminary biochemical evaluation of novel derivatives of PCP.” Their research was published in the journal Letters in Drug Design & Discovery, Volume 7 (2). You can access this study through DOI: 10.2174/157018010790225813.
  2. Wallach J, De Paoli G, Adejare A, and Brandt SD conducted research in 2014 titled “Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues.” This study was published in Drug Testing and Analysis, Volume 6 (7–8) and can be found through DOI: 10.1002/dta.1468. The PMID for this study is 23554350.
  3. Maddox VH, Godefroi EF, and Parcell RF were pioneers in the field and, in March 1965, conducted “The synthesis of phencyclidine and other 1-arylcyclohexylamines.” This early research was published in the Journal of Medicinal Chemistry, Volume 8 (2), and is available through DOI: 10.1021/jm00326a019. The PMID for this historical study is 14332667.
  4. On January 28, 2021, Jankovic M contributed to the “EU Early Warning System,” which plays a crucial role in monitoring new psychoactive substances in Europe. This information can be accessed online through the responsible authorities.
  5. The European Commission released information on the “Amendment of Minister for Human Capacities Decree No 55/2014 of 30 December 2014 on substances or groups of compounds classified as new psychoactive substances, 2021/225/HU.” This amendment is available through the European Commission’s official channels.

Leave a Comment

Your email address will not be published. Required fields are marked *